Oxford's Covid vaccine given, volunteers to be observed for 28 days, says SII's Adar Poonawalla

▴ Oxford's Covid vaccine given, volunteers to be observed for 28 days, says SII's Adar Poonawalla
In India, the ICMR has funded the clinical trial site fees while SII is taking care of other expenses for the University of Oxford and AstraZeneca's coronavirus vaccine 'Covishield'.

Adar Poonawalla, CEO of Pune-based SII told India Today, "We are at the last mile. All of the 1,600 volunteers have been administered with required dozes of COVISHIELD vaccine and now all of them are under observation for the next 28 days."

The Serum Institute of India (SII) along with AstraZeneca has partnered with the University of Oxford for the development of its novel coronavirus vaccine 'Covishield'.

On Thursday, the SII and the Indian Council of Medical Research (ICMR) announced the completion of enrolment of phase 3 clinical trials for 'Covishield' in India. The ICMR and SII have further collaborated for the clinical development of 'COVOVAX' developed by US Pharma giant Novavax and upscaled by the SII.

Covishield coronavirus vaccine
In India, ICMR has funded the clinical trial site fees while SII is taking care of other expenses for 'Covishield'. At present, SII and ICMR are conducting Phase 2/3 clinical trials of 'Covishield' at 15 different centers across the country.

The enrollment of all 1,600 participants was complete by October 31.

Developed at the University of Oxford in the UK, the vaccine is being tested in large efficacy trials in the UK, Brazil, South Africa, and the USA.

Pune-based SII has already manufactured 40 million doses of the vaccine under the scope of at-risk manufacturing and stockpiling license from DCGI.

SII CEO Adar Poonawalla told India Today, "ICMR has played a huge role in coming forward and strengthening India's fight against Covid-19. The collaboration will further aid us in putting India at the forefront of developing an immunogenic and efficacious vaccine."

story credit ; www.indiatoday.in 

Tags : #SerumInstituteINdia #OxfordCovidVaccine #CovishieldNewsNov13 #Covovax #Novavax #ICMR #latestCovidVaccineNewsNov13

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026